BioGaia develops and sells probiotic products based primarily on the bacterial strain Limosilactobacillus reuteri. Its range includes drops, tablets and other formats aimed at gut health, often for infants, children and everyday consumer use, sold through pharmacies, retail and healthcare channels. The company is known for research-backed probiotic brands rather than broad pharmaceutical manufacturing.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q4 2024 | 364.8 | — | 81.9 | — |
| Q1 2025 | 366.3 | — | 80.2 | — |
| Q2 2025 | 404.7 | — | 87.9 | — |
| Q4 2025 | 440.6 | 20.8% | 98.8 | 20.6% |
| Q1 2026 | 372.6 | 1.7% | 79.4 | -1% |
| Q2 2026 | 440.9 | 8.9% | 103.2 | 17.4% |
All markets — KeepWinning global stock screener
Other companies on Stockholm: Viaplay Group AB (publ) (VPLAY A), MilDef Group AB (publ) (MILDEF), Vitec Software Group AB (publ) (VIT B), Plejd AB (publ) (PLEJD), Inwido AB (publ) (INWI), engcon AB (publ) (ENGCON B)